EGFR and carcinoma of esophagus: The development and clinical use of EGFR inhibitors for oesophageal cancer, however, has been hampered by conflicting trial results, which could be a consequence of biomarker-unselected patient cohorts, and also because questions regarding potential antagonistic effects of co-administration of EGFR inhibitors with cytotoxic chemotherapy have been raised [25–28].